FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2333604950> ?p ?o ?g. }

• W2333604950 endingPage "252" @default.
• W2333604950 startingPage "251.2" @default.
• W2333604950 abstract "<h3>Background</h3> Better objectives measures for evaluating disease activity and anti-TNFα response in patients with AS are needed. In this sense, MMP-3 seems to be the most promising biomarker although published data are not conclusive (1). Moreover, there is no evidence anti-TNFα therapy inhibit radiological progression, which has brought the concern if inflammation and bone proliferation are or not related processes (2-5). The study of biomarkers implicated in these processes such as dikkopf-1 (DKK-1) and sclerostin will help us to understand it. <h3>Objectives</h3> To evaluate the change of MMP-3, DKK-1 and sclerostin serum levels after anti-TNFα therapy and to investigate if any of them are correlated with disease activity or can be useful to predict anti-TNFα response in patients with AS. <h3>Methods</h3> From November 2012 to July 2011, patients with AS (New York criteria) who initiated anti-TNFα therapy in a University hospital were included. Socio-demographic and disease characteristics variables were recorded at baseline. Before and after 3 months of therapy, disease activity was measured, and blood samples for determination of serum levels of MMP-3, DKK-1 and sclerostin by enzymoinmunoanalysis were collected. Treatment response was defined using BASDAI50 and ASDAS response. The Wilcoxon test was used for evaluations of changes under treatment and the Mann-Whitney U test for between-group comparisons. Receiver operating characteristic analysis to determine the accuracy to predict response and Correlation testing were performed. <h3>Results</h3> A total of 20 AS patients were included, 86% men, 42.4 (31-49) years old, with disease duration 6.8 (3-10) years, 83% HLA-27 positive, from which 80% and 20% received adalimumab and etanercept, respectively. After 3 months of anti-TNFα, all disease activity parameters improved significantly (BASDAI 6.5 vs 3.6; p=0.001, ASDAS 3.6 vs 2.1; p<0.001, CRP 13.5 vs 4.4 mg/L; p=0.001). Serum levels of MMP-3 decreased (100.0 ng/ml vs 68.1; p<0.05) while levels of DKK-1 and sclerostin did not change significantly (7.07 pmol/l vs 7.65; P=0.5 and 21.7 pmol/l vs 22.7, p=0.5, respectively). A significant correlation was only found between baseline levels of MMP-3 and pain VAS. Moreover, we compared biomarker changes based on treatment response, and observed that MMP-3 decreased only in patients who responded to anti-TNF therapy (122.2 ng/ml vs 64.1; p=0.01). Baseline serum levels of MMP-3 were significantly higher in patients who had a good response to anti-TNFα vs those who did not respond (122.9 ng/ml vs 58.9; p<0.05). The area under the curve for MMP-3 to predict BASDAI50 and ASDAS response was 0.73 and 0.78, respectively. The best cut-off was established for levels higher than 59.5 ng/ml, with sensibility of 79-85% and specificity of 50-57%. <h3>Conclusions</h3> Serum levels of MMP-3 decreased after anti-TNF therapy and were useful to predict response to this therapy in patients with AS. There was no correlation between serum levels of MMP-3, DKK-1 or sclerostin and disease activity parameters. <h3>References</h3> Sieper J. Curr Opin Rheumatol. 2009 Jul;21(4):335-9 Chen CH et al. Rheumatology 2006;45:414–420 Wendling D et al. Joint Bone Spine. 2008 Oct;75(5):559-62 Arends S et al. J Rheumatol. 2011 Aug;38(8):1644-50 Wendling D et al. J Rheumatol. 2007 Aug;34(8):1647-9 <h3>Disclosure of Interest</h3> None Declared" @default.
• W2333604950 created "2016-06-24" @default.
• W2333604950 creator A5004785180 @default.
• W2333604950 creator A5021215710 @default.
• W2333604950 creator A5037385421 @default.
• W2333604950 creator A5055764091 @default.
• W2333604950 creator A5060165693 @default.
• W2333604950 creator A5071210330 @default.
• W2333604950 creator A5072690427 @default.
• W2333604950 date "2013-06-01" @default.
• W2333604950 modified "2023-10-01" @default.
• W2333604950 title "THU0284 Metalloproteinase-3 (MMP-3) is a predictor for anti-TNFα response in patients with ankylosing spondylitis (AS)" @default.
• W2333604950 doi "https://doi.org/10.1136/annrheumdis-2012-eular.2249" @default.
• W2333604950 hasPublicationYear "2013" @default.
• W2333604950 type Work @default.
• W2333604950 sameAs 2333604950 @default.
• W2333604950 citedByCount "0" @default.
• W2333604950 crossrefType "journal-article" @default.
• W2333604950 hasAuthorship W2333604950A5004785180 @default.
• W2333604950 hasAuthorship W2333604950A5021215710 @default.
• W2333604950 hasAuthorship W2333604950A5037385421 @default.
• W2333604950 hasAuthorship W2333604950A5055764091 @default.
• W2333604950 hasAuthorship W2333604950A5060165693 @default.
• W2333604950 hasAuthorship W2333604950A5071210330 @default.
• W2333604950 hasAuthorship W2333604950A5072690427 @default.
• W2333604950 hasConcept C104317684 @default.
• W2333604950 hasConcept C126322002 @default.
• W2333604950 hasConcept C12868164 @default.
• W2333604950 hasConcept C137620995 @default.
• W2333604950 hasConcept C143998085 @default.
• W2333604950 hasConcept C17991360 @default.
• W2333604950 hasConcept C185592680 @default.
• W2333604950 hasConcept C1862650 @default.
• W2333604950 hasConcept C206041023 @default.
• W2333604950 hasConcept C2776260265 @default.
• W2333604950 hasConcept C2777226972 @default.
• W2333604950 hasConcept C2777402515 @default.
• W2333604950 hasConcept C2777453003 @default.
• W2333604950 hasConcept C2779134260 @default.
• W2333604950 hasConcept C2779277721 @default.
• W2333604950 hasConcept C2779722408 @default.
• W2333604950 hasConcept C2781197716 @default.
• W2333604950 hasConcept C55493867 @default.
• W2333604950 hasConcept C71924100 @default.
• W2333604950 hasConceptScore W2333604950C104317684 @default.
• W2333604950 hasConceptScore W2333604950C126322002 @default.
• W2333604950 hasConceptScore W2333604950C12868164 @default.
• W2333604950 hasConceptScore W2333604950C137620995 @default.
• W2333604950 hasConceptScore W2333604950C143998085 @default.
• W2333604950 hasConceptScore W2333604950C17991360 @default.
• W2333604950 hasConceptScore W2333604950C185592680 @default.
• W2333604950 hasConceptScore W2333604950C1862650 @default.
• W2333604950 hasConceptScore W2333604950C206041023 @default.
• W2333604950 hasConceptScore W2333604950C2776260265 @default.
• W2333604950 hasConceptScore W2333604950C2777226972 @default.
• W2333604950 hasConceptScore W2333604950C2777402515 @default.
• W2333604950 hasConceptScore W2333604950C2777453003 @default.
• W2333604950 hasConceptScore W2333604950C2779134260 @default.
• W2333604950 hasConceptScore W2333604950C2779277721 @default.
• W2333604950 hasConceptScore W2333604950C2779722408 @default.
• W2333604950 hasConceptScore W2333604950C2781197716 @default.
• W2333604950 hasConceptScore W2333604950C55493867 @default.
• W2333604950 hasConceptScore W2333604950C71924100 @default.
• W2333604950 hasIssue "Suppl 3" @default.
• W2333604950 hasLocation W23336049501 @default.
• W2333604950 hasOpenAccess W2333604950 @default.
• W2333604950 hasPrimaryLocation W23336049501 @default.
• W2333604950 hasRelatedWork W1969455977 @default.
• W2333604950 hasRelatedWork W2165188789 @default.
• W2333604950 hasRelatedWork W2171255147 @default.
• W2333604950 hasRelatedWork W2333604950 @default.
• W2333604950 hasRelatedWork W2411482347 @default.
• W2333604950 hasRelatedWork W2754289805 @default.
• W2333604950 hasRelatedWork W2913836612 @default.
• W2333604950 hasRelatedWork W3165682585 @default.
• W2333604950 hasRelatedWork W4200158927 @default.
• W2333604950 hasRelatedWork W4235629817 @default.
• W2333604950 hasVolume "71" @default.
• W2333604950 isParatext "false" @default.
• W2333604950 isRetracted "false" @default.
• W2333604950 magId "2333604950" @default.
• W2333604950 workType "article" @default.